Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit
the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the …

Purpose Abiraterone acetate (AA) plus prednisone is an approved treatment of advanced
prostate cancer (PCa). Autophagy is linked to drug resistance in numerous types of cancers …

Abstract Background ARN-509 (Apalutamide) is a unique androgen receptor (AR)
antagonist for the treatment of castration-resistant (CR) prostate cancer (PC). It inhibits AR …

Tyrosine kinases play significant roles in tumor progression and therapy resistance.
Inhibitors of tyrosine kinases are on the forefront of targeted therapy. For prostate cancer …

Introduction and Objectives Multiple androgen receptor (AR)‐dependent and‐independent
resistance mechanisms limit the efficacy of current castration‐resistant prostate cancer …

What's known on the subject? and What does the study add? Androgen‐ablation therapy
(AAT) and chemotherapy are commonly used to treat incurable prostate cancer. To improve …

BACKGROUND Treatment of advanced prostate cancer (PCa) relies on pharmacological or
surgical androgen deprivation. However, it is only temporarily efficient. After a few months or …

Objectives: Although androgen deprivation therapy remains the standard treatment for the
initial therapy of advanced prostate cancer (PC), castration does not eliminate persistent …

Context: Bisbibenzyl compounds have gained our interests for their potential antitumor
activity in malignant cell-types. Objective: The objective of this study is to investigate the …

Cabazitaxel has been used to treat castration-resistant prostate cancer since its approval by
the US Food and Drug Administration in 2010. However, whether cabazitaxel may inhibit the …